BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

January 27, 2014 8:00 AM UTC

AB Science S.A. (Euronext:AB) fell €2.95 (21%) to €11.36 on Friday after EMA's CHMP recommended against approval of Masiviera masitinib for first-line treatment of non-resectable locally advanced or metastatic pancreatic cancer in combination with gemcitabine.

According to CHMP, masitinib was not effective in the overall group of pancreatic cancer patients. The committee also was concerned about masitinib's toxicity and with impurities and the quality of potential commercial batches of the compound...